MedTrace Logo

Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00929708 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 329

Last updated 2014-02-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.

Conditions

Interventions

DRUG

AZD3199

Dry powder for inhalation, o.d., 4 weeks

DRUG

formoterol

Dry powder for inhalation, b.i.d., 4 weeks

DRUG

Placebo

Dry powder for inhalation, b.i.d., 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Piotr Kuna, Professor · University Hospital, Lodz, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Bulgaria
  • Canada
  • Japan
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929708 on ClinicalTrials.gov